Gland Pharma Limited (BSE: 543245 I NSE: GLAND), a generic injectable-focused pharmaceutical company, today announced its financial results for the Second quarter (Q2FY25) ended on September 30th, 2024. Financial Highlights Q2 FY25 (July 2024 to September 2024) • Consolidated revenue increased 2% year-over-year to INR 14,058 million. • Consolidated EBITDA decreased
Gland Pharma Limited (Gland or Company), a generic injectable-focused pharmaceutical company, has received tentative approval from the United States Food and Drug Administration (USFDA) for Latanoprostene Bunod Ophthalmic Solution, 0.024%. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vyzulta® Ophthalmic Solution,
Gland Pharma Limited (BSE: 543245 I NSE: GLAND), a generic injectable-focused pharmaceutical company, today announced that Srinivas Sadu, the incumbent Managing Director (MD) and CEO, has been appointed as Executive Chairman and CEO of the company, effective June 10, 2024. Srinivas Sadu, a seasoned professional with
